The safety and immunogenicity of a CETP vaccine in healthy adults

Atherosclerosis. 2003 Jul;169(1):113-20. doi: 10.1016/s0021-9150(03)00137-0.


A cholesterol ester transfer protein (CETP) vaccine (CETi-1) that induces auto-antibodies that specifically bind and inhibit activity of endogenous CETP has been demonstrated in rabbits to significantly increase HDL-C and reduce the development of atherosclerosis. In a Phase I human trial with CETi-1, one patient at the highest dose (250 mg) out of a total of 36 patients who received a single injection developed anti-CETP antibodies. In an extension study of 23 patients, 53% (8/15) who received a second injection of the active vaccine developed anti-CETP antibodies compared with 0% (0/8) in the placebo group. The vaccine was well tolerated and no significant laboratory abnormalities occurred. CETi-1 is a feasible therapy in humans to induce CETP auto-antibodies. Future research will determine if repeat inoculations will induce a sufficient anti-CETP antibody response to inhibit CETP and increase HDL levels.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Autoantibodies / biosynthesis*
  • Carrier Proteins / immunology*
  • Cholesterol Ester Transfer Proteins
  • Cholesterol Esters / immunology*
  • Cholesterol, HDL / blood
  • Dose-Response Relationship, Immunologic
  • Double-Blind Method
  • Glycoproteins*
  • Humans
  • Vaccines, Synthetic / adverse effects
  • Vaccines, Synthetic / immunology*


  • Autoantibodies
  • CETP protein, human
  • Carrier Proteins
  • Cholesterol Ester Transfer Proteins
  • Cholesterol Esters
  • Cholesterol, HDL
  • Glycoproteins
  • Vaccines, Synthetic